Investor Relations

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMRTSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira has established itself as a global leader in the RNAi field. Tekmira has a diverse pipeline of product candidates in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company is advancing the development of novel drugs in areas where there is a significant unmet medical need and commercial opportunity. Tekmira also licenses its leading LNP delivery technology to partners around the world.

View all »   RSSRecent Releases

Sep 23, 2014
Tekmira Joins International Consortium to Conduct Clinical Trials of Ebola Virus Therapeutics in West Africa

Aug 20, 2014
Tekmira's Lipid Nanoparticle (LNP) Technology Targeting Marburg Virus Highlighted in Scientific Publication


View all »Events & Presentations

Oct 15, 2014
10th Annual Meeting of the Oligonucleotide Therapeutics Society

Oct 7, 2014
2014 BIO Investor Forum